Autolus enters 10-year lentiviral vector supply deal with AGC Biologics

Autolus Therapeutics plc

Master Service Agreement with AGC Biologics for lentiviral vector, critical for CAR-T production.
Minimum purchase: 14 batches in first 2 years; EUR 25 million over subsequent 5 years.
AGC granted first right to negotiate manufacturing of obe-cel (obecabtagene autoleucel).
10-year fixed term, non-exclusive; Autolus can terminate with certain fees, either party for default.
Agreement replaces prior arrangement; individual work orders govern specific projects.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Autolus Therapeutics plc entered into Master Service Agreement with AGC Biologics S.p.A. valued at EUR 25 million (effective 2026-01-21).

Action: entry
Agreement: supply
Counterparty: AGC Biologics S.p.A.
Value: EUR 25 million
Effective: 2026-01-21

Exact text from the filing

On January 21, 2026, Autolus Limited, a wholly owned subsidiary of Autolus Therapeutics plc (the “ registrant ”, and together with Autolus Limited, the “ Company ”), entered into a Master Service Agreement with AGC Biologics S.p.A (“ AGC ”) for the manufacture and supply of lentiviral vector (the “ Agreement ”)

View on SEC.gov

269 material agreements filed in the last 30 days. Browse all material agreements →

Autolus Therapeutics plc filing history →

Source: SEC EDGAR

accession 0001730463-26-000019

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.